<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>FORM S-3 — Pulse Biosciences, Inc.</title>
<style>
body { font-family: Arial, Helvetica, sans-serif; background:#0f1115; color:#e6e6e6; margin:0; padding:40px; }
.container { max-width:700px; margin:auto; background:#161a21; border-radius:10px; padding:32px; box-shadow:0 0 30px rgba(0,0,0,0.4); }
h1 { margin-top:0; color:#4da3ff; }
table { width:100%; margin-top:12px; border-collapse:collapse; }
th, td { text-align:left; padding:6px 8px; border-bottom:1px solid #2a2f3a; }
ul { margin-top:12px; padding-left:20px; }
.section { margin-top:24px; }
.small { margin-top:12px; font-size:13px; color:#999; }
a { color:#4da3ff; }
</style>
</head>
<body>
  <div class="container">
    <h1>FORM S-3 — Pulse Biosciences, Inc.</h1>

    <table>
      <tr><th>Ticker</th><td>PLSE</td></tr>
      <tr><th>Float</th><td>N/A</td></tr>
      <tr><th>IO</th><td>N/A</td></tr>
      <tr><th>MC</th><td>N/A</td></tr>
      <tr><th>Extra Info</th><td>None</td></tr>
    </table>

    <div class="section">
      <strong>Summary</strong>
      <p>Registration statement on Form S-3 filed by Pulse Biosciences, Inc. to register an aggregate offering amount of up to $200,000,000 of various securities (common stock, preferred stock, debt securities, depositary shares, warrants, subscription rights, purchase contracts and units) on a shelf/’at‑the‑market’ basis. The prospectus notes the company’s common stock trades on the Nasdaq Capital Market under ticker PLSE (last reported sale $25.46 on February 18, 2026). Corporate facts disclosed: authorized capital of 500,000,000 common shares and 50,000,000 preferred shares; 67,839,689 shares of common stock issued and outstanding as of December 31, 2025 held by 11 stockholders of record. The filing incorporates by reference the company’s recent 10‑K (fiscal year ended December 31, 2025) and certain 8‑K filings and includes standard risk factor disclosures, plan of distribution options, description of securities, and corporate governance/anti‑takeover provisions.</p>
    </div>

    <div class="section">
      <strong>Positives</strong>
      <ul><li>Form S-3 shelf registration authorizes offers up to $200,000,000 of multiple security types (common, preferred, debt, warrants, etc.), providing financing flexibility.</li><li>Common stock listed on Nasdaq under ticker PLSE (last reported sale $25.46 on 02/18/2026).</li><li>Provides multiple distribution methods including 'at‑the‑market', underwritten offerings, negotiated transactions and direct sales.</li><li>Discloses issued and outstanding common shares: 67,839,689 as of December 31, 2025 (11 stockholders of record).</li></ul>
    </div>

    <div class="section">
      <strong>Negatives</strong>
      <ul><li>Prospectus states investing involves a high degree of risk and refers investors to detailed 'Risk Factors' in the prospectus and incorporated filings.</li><li>Board of directors has authority to issue up to 50,000,000 shares of preferred stock without further stockholder approval (could affect common shareholders' rights).</li><li>Corporate charter and bylaws include anti‑takeover and transfer provisions (advance notice requirements, limits on action by written consent, Delaware Section 203, exclusive choice of forum provisions).</li><li>Registration allows issuance 'from time to time' which could result in future dilution if securities are sold (amounts, prices and timing to be specified in prospectus supplements).</li></ul>
    </div>

    <div class="section">
      <a href="https://www.sec.gov/Archives/edgar/data/1625101/000143774926004735/0001437749-26-004735-index.htm" target="_blank">Original Article</a>
    </div>

    <div class="small">PLSE • TradersLink AI News</div>
  </div>
</body>
</html>